-
Je něco špatně v tomto záznamu ?
Meta-analysis of randomized controlled trials for the development of the International Federation for Surgery of Obesity and Metabolic Disorders-European Chapter (IFSO-EC) guidelines on multimodal strategies for the surgical treatment of obesity
M. De Luca, A. Belluzzi, L. Angrisani, G. Bandini, B. Becattini, M. Bueter, FM. Carrano, S. Chiappetta, RV. Cohen, C. Copaescu, N. Di Lorenzo, M. Emous, DM. Felsenreich, M. Fried, J. Himpens, A. Iannelli, G. Navarra, S. Nienhuijs, S. Olmi, C....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, metaanalýza
PubMed
40197859
DOI
10.1111/dom.16352
Knihovny.cz E-zdroje
- MeSH
- bariatrická chirurgie * metody MeSH
- hmotnostní úbytek MeSH
- index tělesné hmotnosti MeSH
- kombinovaná terapie MeSH
- kvalita života MeSH
- lidé MeSH
- obezita * chirurgie terapie MeSH
- randomizované kontrolované studie jako téma MeSH
- směrnice pro lékařskou praxi jako téma MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
BACKGROUND: Randomized, controlled trials (RCTs) comparing the effectiveness of metabolic bariatric surgery (MBS) in addition to one or more treatment interventions for obesity (i.e., lifestyle structured interventions-LSI, medical therapy-MT, obesity management medication-OMM or endobariatric procedures-EP) are lacking. This study aims to assess the effectiveness of multiple simultaneous (before or immediately after MBS) interventions for treating obesity. METHODS: We performed a meta-analysis including all RCTs enrolling patients undergoing different MBS procedures add-on to other anti-obesity strategies (LSI, MT, OMM or ES) versus MBS alone, with a duration of at least 6 months. The primary outcome was BMI at the end-point; secondary end-points included percentage total and excess weight loss (%TWL%, and EBWL%), total weight loss (TWL), fasting plasma glucose (FPG), HbA1c, surgical and non-surgical severe adverse events (SAE), mortality, remission of type 2 diabetes, hypertension, dyslipidemia and health-related quality of life (HR-QoL). RESULTS: A total of 25 RCTs were retrieved. The addition of either OMM (i.e., liraglutide) or EP (i.e., intragastric balloon-IB, endosleeve-ES) to MBS was associated with a significantly lower BMI at the end-point (p = 0.040). The addition of liraglutide only to MBS was associated with a greater %EWL%, but not %TWL and TBWL (p = 0.008). Three trials evaluated end-point HbA1c, showing a significant reduction in favour of liraglutide as an add-on therapy to MBS (p = 0.007). There was no mortality. CONCLUSIONS: MBS combined with non-surgical approaches appears more effective than MBS alone in reducing BMI. Further RCTs on combined therapies to MBS for severe obesity are needed to enhance the tailoring of treatment for severe obesity.
Delta CHIREC Hospital Brussels Belgium
Department of General Emergency and Metabolic Surgery Rovigo Hospital Rovigo Italy
Department of General Surgery Holy Family Hospital Nazareth Israel
Department of Molecular and Clinical Medicine Institute of Medicine Göteborg Sweden
Department of Surgery Catharina Hospital Eindhoven The Netherlands
Department of Surgery Cerrahpasa Medical Faculty Istanbul University Istanbul Turkey
Department of Surgery Faculty of Medicine and Health Örebro University Örebro Sweden
Department of Surgery Ponderas Academic Hospital Bucharest Romania
Department of Surgery University of Turku Turku Finland
Department of Surgery Whittington Hospital University College London UK
Department of Surgical Sciences University of Tor Vergata Rome Italy
Diabetic Foot Unit University of Florence and AOU Careggi Florence Italy
Digestive Surgery and Liver Transplantation Unit Université Côte d'Azur Nice France
OB Klinika Center for Treatment of Obesity and Metabolic Disorders Prague Czech Republic
Public Health Department School of Medicine University Federico 2 of Naples Naples Italy
San Marco Hospital GSD Zingonia Italy
The Azrieli Faculty of Medicine Bar Ilan University Ramat Gan Israel
The Center for Obesity and Diabetes Hospital Alemao Oswaldo Cruz Sao Paulo Brazil
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015500
- 003
- CZ-PrNML
- 005
- 20250731091028.0
- 007
- ta
- 008
- 250708s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/dom.16352 $2 doi
- 035 __
- $a (PubMed)40197859
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a De Luca, Maurizio $u Department of General, Emergency and Metabolic Surgery, Rovigo Hospital, Rovigo, Italy
- 245 10
- $a Meta-analysis of randomized controlled trials for the development of the International Federation for Surgery of Obesity and Metabolic Disorders-European Chapter (IFSO-EC) guidelines on multimodal strategies for the surgical treatment of obesity / $c M. De Luca, A. Belluzzi, L. Angrisani, G. Bandini, B. Becattini, M. Bueter, FM. Carrano, S. Chiappetta, RV. Cohen, C. Copaescu, N. Di Lorenzo, M. Emous, DM. Felsenreich, M. Fried, J. Himpens, A. Iannelli, G. Navarra, S. Nienhuijs, S. Olmi, C. Parmar, G. Prager, J. Pujol-Rafols, B. Ragghianti, R. Ribeiro, E. Ruiz-Úcar, N. Sakran, P. Salminen, D. Scoccimarro, E. Stenberg, C. Stier, HE. Taskin, RV. Puy, M. Monami, Panel for the IFSO‐EC on the Surgical Treatment of Obesity Using Multimodal Strategies
- 520 9_
- $a BACKGROUND: Randomized, controlled trials (RCTs) comparing the effectiveness of metabolic bariatric surgery (MBS) in addition to one or more treatment interventions for obesity (i.e., lifestyle structured interventions-LSI, medical therapy-MT, obesity management medication-OMM or endobariatric procedures-EP) are lacking. This study aims to assess the effectiveness of multiple simultaneous (before or immediately after MBS) interventions for treating obesity. METHODS: We performed a meta-analysis including all RCTs enrolling patients undergoing different MBS procedures add-on to other anti-obesity strategies (LSI, MT, OMM or ES) versus MBS alone, with a duration of at least 6 months. The primary outcome was BMI at the end-point; secondary end-points included percentage total and excess weight loss (%TWL%, and EBWL%), total weight loss (TWL), fasting plasma glucose (FPG), HbA1c, surgical and non-surgical severe adverse events (SAE), mortality, remission of type 2 diabetes, hypertension, dyslipidemia and health-related quality of life (HR-QoL). RESULTS: A total of 25 RCTs were retrieved. The addition of either OMM (i.e., liraglutide) or EP (i.e., intragastric balloon-IB, endosleeve-ES) to MBS was associated with a significantly lower BMI at the end-point (p = 0.040). The addition of liraglutide only to MBS was associated with a greater %EWL%, but not %TWL and TBWL (p = 0.008). Three trials evaluated end-point HbA1c, showing a significant reduction in favour of liraglutide as an add-on therapy to MBS (p = 0.007). There was no mortality. CONCLUSIONS: MBS combined with non-surgical approaches appears more effective than MBS alone in reducing BMI. Further RCTs on combined therapies to MBS for severe obesity are needed to enhance the tailoring of treatment for severe obesity.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a bariatrická chirurgie $x metody $7 D050110
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 650 12
- $a obezita $x chirurgie $x terapie $7 D009765
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a hmotnostní úbytek $7 D015431
- 650 _2
- $a směrnice pro lékařskou praxi jako téma $7 D017410
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a kvalita života $7 D011788
- 650 _2
- $a index tělesné hmotnosti $7 D015992
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 700 1_
- $a Belluzzi, Amanda $u Department of General, Emergency and Metabolic Surgery, Rovigo Hospital, Rovigo, Italy
- 700 1_
- $a Angrisani, Luigi $u Public Health Department, School of Medicine, University Federico II of Naples, Naples, Italy
- 700 1_
- $a Bandini, Giulia $u Diabetic Foot Unit, University of Florence and AOU-Careggi, Florence, Italy
- 700 1_
- $a Becattini, Barbara $u Department of Molecular and Clinical Medicine, Institute of Medicine, Göteborg, Sweden
- 700 1_
- $a Bueter, Marco $u Department of Surgery and Transplantation, University Hospital Zurich, University of Zurich, Zurich, Switzerland
- 700 1_
- $a Carrano, Francesco Maria $u Department of Medical Surgical Sciences and Translational Medicine, Sant'Andrea Hospital, Sapienza University, Rome, Italy
- 700 1_
- $a Chiappetta, Sonja $u Bariatric and Metabolic Surgery Unit, Department of General and Laparoscopic Surgery, Ospedale Evangelico Betania, Naples, Italy
- 700 1_
- $a Cohen, Ricardo V $u The Center for Obesity and Diabetes, Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil
- 700 1_
- $a Copaescu, Catalin $u Department of Surgery, Ponderas Academic Hospital, Bucharest, Romania
- 700 1_
- $a Di Lorenzo, Nicola $u Department of Surgical Sciences, University of Tor Vergata, Rome, Italy
- 700 1_
- $a Emous, Marloes $u Department of Bariatric and Metabolic Surgery, Medical Center, Center for Obesity Northern-Netherlands (CON), Leeuwarden, The Netherlands
- 700 1_
- $a Felsenreich, Daniel Moritz $u Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Fried, Martin $u OB Klinika-Center for Treatment of Obesity and Metabolic Disorders, Prague, Czech Republic
- 700 1_
- $a Himpens, Jacques $u Delta CHIREC Hospital (Belgian Registry), Brussels, Belgium
- 700 1_
- $a Iannelli, Antonio $u Digestive Surgery and Liver Transplantation Unit, Université Côte d'Azur, Nice, France
- 700 1_
- $a Navarra, Giuseppe $u University of Messina, Messina, Italy
- 700 1_
- $a Nienhuijs, Simon $u Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands
- 700 1_
- $a Olmi, Stefano $u San Marco Hospital GSD, Zingonia, Italy
- 700 1_
- $a Parmar, Chetan $u Department of Surgery, Whittington Hospital, University College, London, UK
- 700 1_
- $a Prager, Gerhard $u Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Pujol-Rafols, Juan $u HM Delfos, Barcelona, Spain
- 700 1_
- $a Ragghianti, Benedetta $u Diabetic Foot Unit, University of Florence and AOU-Careggi, Florence, Italy
- 700 1_
- $a Ribeiro, Rui $u Centro Multidisciplinar Do Tratamento da Obesidade, Hospital Lusíadas Amadora e Lisboa, Amadora, Portugal
- 700 1_
- $a Ruiz-Úcar, Elena $u General and Digestive Surgery Department, Fuenlabrada University Hospital, Rey Juan Carlos University, Madrid, Spain
- 700 1_
- $a Sakran, Nasser $u Department of General Surgery, Holy Family Hospital, Nazareth, Israel $u The Azrieli Faculty of Medicine, Bar-Ilan University, Ramat Gan, Israel
- 700 1_
- $a Salminen, Paulina $u Department of Surgery, University of Turku, Turku, Finland
- 700 1_
- $a Scoccimarro, Daniele $u Diabetic Foot Unit, University of Florence and AOU-Careggi, Florence, Italy
- 700 1_
- $a Stenberg, Erik $u Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden $1 https://orcid.org/0000000191890093
- 700 1_
- $a Stier, Christine $u Department of Surgery, Bariatric Endoscopy, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany
- 700 1_
- $a Taskin, Halit Eren $u Department of Surgery, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
- 700 1_
- $a Puy, Ramón Vilallonga $u Endocrine-Metabolic and Bariatric Surgery Unit, Vall Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain
- 700 1_
- $a Monami, Matteo $u Diabetic Foot Unit, University of Florence and AOU-Careggi, Florence, Italy $1 https://orcid.org/000000019349828X
- 710 2_
- $a Panel for the IFSO‐EC on the Surgical Treatment of Obesity Using Multimodal Strategies
- 773 0_
- $w MED00005425 $t Diabetes, obesity and metabolism $x 1463-1326 $g Roč. 27, č. 6 (2025), s. 3347-3356
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40197859 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091023 $b ABA008
- 999 __
- $a ok $b bmc $g 2366379 $s 1252625
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 27 $c 6 $d 3347-3356 $e 20250408 $i 1463-1326 $m Diabetes, obesity and metabolism $n Diabetes Obes Metab $x MED00005425
- LZP __
- $a Pubmed-20250708
